Skip to main content
. 2016 Mar;22(3):e151430. doi: 10.3201/eid2203.151430

Figure 2.

Figure 2

Global progress on the programmatic use of delamanid (DLM) to treat multidrug-resistant tuberculosis. Red shading indicates countries using DLM under program conditions. Gray indicates countries that have not reported using DLM under program conditions.